On November 7, 2025 Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A. and a clinical-stage biotech company discovering and developing innovative therapies for the treatment of cancer, reported its poster at the World ADC Summit 2025, highlighting its next-generation payload-linker technologies designed to overcome key limitations of current ADC modalities. The poster, titled "Next-Generation ADC Payloads: Redefining Targeted Cancer Therapy" (link to download), attracted strong interest from the ADC community.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These payload-linker innovations represented an important step forward for ADC development, enabling an improved balance between potency and safety, activity in chemo-resistant tumors, and novel mechanisms that go beyond conventional DNA-damaging payloads.

Expanding the Therapeutic Reach of ADCs

Leveraging its proven expertise in drug development, NMS has advanced a portfolio of novel payloads designed to address the long-standing challenges in ADC design and therapeutic scope.

The NMS ADC payload portfolio includes:

Duocarmycins that demonstrated high in-vivo efficacy across multiple tumor models with a favorable safety profile, well-suited for chemo-resistant, highly heterogeneous solid tumors;
Anthracyclines engineered to achieve an improved balance between potency and safety while exhibiting unique immune-activating properties; and
Targeted payloads acting beyond DNA damage, offering strong potential for dual-payload combinations and activity across multiple oncogenic pathways.
By introducing these differentiated payload–linker technologies, NMS aims to broaden the range of targetable tumors and drive oncology toward durable, immune-mediated cancer control.

"We continue to innovate in payload-linker chemistry, enabling the design of novel ADCs that address unmet medical needs and expand treatment options for patients currently beyond the reach of existing therapies," said Tomasz Rzymski, Chief Scientific Officer, NMS ADC Business Unit. "We plan to further invest in our integrated R&D platform to accelerate the development of differentiated payload-linker classes and next-generation ADCs, while also exploring strategic collaborations to bring these therapies closer to patients."

(Press release, Nerviano Medical Sciences, NOV 7, 2025, View Source [SID1234659637])